Oruka Therapeutics, INC Form 4 insider transactions

Oruka Therapeutics Chief Operating Officer Laura Lee Sandler exercised 5,000 stock options and sold 5,000 shares under a pre-arranged 10b5-1 trading plan.

Chief Medical Officer Joana Goncalves exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Oruka Therapeutics CEO Lawrence Klein sold 1,729 shares of common stock at $41.3 per share to cover tax withholding obligations.

Oruka Therapeutics' Senior Vice President of Finance, Arjun Agarwal, sold 395 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Oruka Therapeutics' Chief Operating Officer, Laura Lee Sandler, sold 600 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Oruka Therapeutics' Chief Medical Officer, Joana Goncalves, reported exercising stock options and warrants while selling common stock, including shares under a 10b5-1 plan and for tax obligations.

Oruka Therapeutics' General Counsel, Paul T. Quinlan, sold 733 shares of common stock at $41.3 per share to cover tax withholding obligations related to restricted stock unit vesting.

Oruka Therapeutics' Chief Operating Officer, Laura Sandler, exercised options and subsequently sold an equivalent number of shares under a pre-arranged trading plan.

Oruka Therapeutics' Chief Medical Officer, Joana Goncalves, reported the acquisition of 32,500 common shares and 130,000 employee stock options.

Oruka Therapeutics' Chief Operating Officer, Laura Lee Sandler, received grants of 32,500 common shares and options for 130,000 shares.

Arjun Agarwal, SVP of Finance at Oruka Therapeutics, Inc., reported the acquisition of 17,500 common shares and 70,000 employee stock options through grants.

Oruka Therapeutics, Inc. CEO Lawrence Otto Klein was granted 76,700 shares of common stock and options to purchase 306,700 shares.

Oruka Therapeutics General Counsel Paul T. Quinlan received a grant of 32,500 common shares and 130,000 employee stock options.

Oruka Therapeutics Director Carl Dambkowski reported the acquisition of 116,483 shares of common stock through a pro-rata distribution from an LLC.

Oruka Therapeutics' Chief Medical Officer, Joana Goncalves, exercised stock options and warrants, then sold a portion of the acquired common stock under a pre-arranged trading plan.

Oruka Therapeutics' Chief Operating Officer, Laura Lee Sandler, reported exercising warrants and selling a portion of her common stock holdings.

Oruka Therapeutics' Chief Medical Officer, Joana Goncalves, exercised stock options and warrants, then sold a portion of her common stock holdings under a pre-arranged trading plan.

Oruka Therapeutics, Inc. director Christopher Nathan received a grant of 35,000 stock options with an exercise price of $30.21, vesting monthly over three years.

Fairmount Funds Management and its affiliates acquired 333,340 shares of Oruka Therapeutics common stock in a private placement for $15 per share.

Oruka Therapeutics, Inc. Chief Operating Officer Laura Lee Sandler was granted 25,000 employee stock options with an exercise price of $11.80, vesting over four years.

Oruka Therapeutics, Inc. has granted 17,500 stock options to entities and individuals associated with Fairmount Funds Management LLC, including directors Peter Harwin and Tomas Kiselak, aligning their interests with the company's long-term performance.

Oruka Therapeutics, Inc. Director Samarth Kulkarni was granted 17,500 stock options with an exercise price of $11.77, vesting monthly from June 2, 2025.

Oruka Therapeutics, Inc. Director Carl Dambkowski was granted 17,500 stock options with an exercise price of $11.77, vesting monthly from June 2, 2025.

Oruka Therapeutics, Inc. Director Cameron Turtle has acquired 17,500 stock options with an exercise price of $11.77, vesting monthly from June 2, 2025.

Oruka Therapeutics, Inc. Director Kristine M. Ball was granted 17,500 stock options with an exercise price of $11.77, vesting monthly from June 2, 2025.

Venrock Healthcare Capital Partners III, L.P. and related entities have increased their holdings in Oruka Therapeutics, Inc. through a series of open market purchases.

Arjun Agarwal, SVP of Finance at Oruka Therapeutics, reported the acquisition of 120,000 stock options on January 22, 2025.

Oruka Therapeutics' Chief Medical Officer, Joana Goncalves, was granted 162,500 stock options on January 22, 2025, which vest monthly starting January 1, 2025.

Oruka Therapeutics' General Counsel, Paul T. Quinlan, has acquired 162,500 stock options, vesting monthly from January 1, 2025.

Oruka Therapeutics' CEO, Lawrence Otto Klein, was granted 230,000 stock options on January 22, 2025, which vest monthly over four years.